Leon Di Stefano

Leon Di Stefano

Auto-generated profile, based on publicly available information

Leon Di Stefano

Bioinformatics Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
DCDaniel L. Cameron
Daniel L. Cameron
LSLeon Di Stefano
Leon Di Stefano
APAnthony T. Papenfuss
Anthony T. Papenfuss
In recent years, many software packages for identifying structural variants (SVs) using whole-genome sequencing data have been released. When published, a new method is commonly compared with those already available, but this tends to be selective and incomplete. The lack of comprehensive benchmarking of methods presents challenges for users in selecting methods and for developers in understanding algorithm behaviours and limitations. Here we report the comprehensive evaluation of 10 SV callers, selected following a rigorous process and spanning the breadth of detection approaches, using high-quality reference cell lines, as well as simulations. Due to the nature of available truth sets, our focus is on general-purpose rather than somatic callers. We characterise the impact on performance of event size and type, sequencing characteristics, and genomic context, and analyse the efficacy of ensemble calling and calibration of variant quality scores. Finally, we provide recommendations for both users and methods developers.

11 June 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AJAna Janic
Ana Janic
LVLiz J. Valente
Liz J. Valente
MWMatthew J. Wakefield
Matthew J. Wakefield
LSLeon Di Stefano
Leon Di Stefano
LMLiz Milla
Liz Milla
MHMarco Herold
Marco Herold

15 February 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Delphine MerinoDelphine Merino
Delphine Merino
TWT. S. Weber
T. S. Weber
ASAntonin Serrano
Antonin Serrano
FVF. Vaillant
F. Vaillant
KLK. Liu
K. Liu
SNS. H. Naik
S. H. Naik
Primary triple negative breast cancers (TNBC) are prone to dissemination but sub-clonal relationships between tumors and resulting metastases are poorly understood. Here we use cellular barcoding of two treatment-naïve TNBC patient-derived xenografts (PDXs) to track the spatio-temporal fate of thousands of barcoded clones in primary tumors, and their metastases. Tumor resection had a major impact on reducing clonal diversity in secondary sites, indicating that most disseminated tumor cells lacked the capacity to ‘seed’, hence originated from ‘shedders’ that did not persist. The few clones that continued to grow after resection i.e. ‘seeders’, did not correlate in frequency with their parental clones in primary tumors. Cisplatin treatment of one BRCA1-mutated PDX model to non-palpable levels had a surprisingly minor impact on clonal diversity in the relapsed tumor yet purged 50% of distal clones. Therefore, clonal features of shedding, seeding and drug resistance are important factors to consider for the design of therapeutic strategies.

29 September 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LSLeon Di Stefano
Leon Di Stefano
EOElizabeth L. Ogburn
Elizabeth L. Ogburn
MRMalathi Ram
Malathi Ram
DSDaniel O. Scharfstein
Daniel O. Scharfstein
TLTianjing Li
Tianjing Li
OAon behalf of the Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses
on behalf of the Pandemic Response COVID-19 Research Collaboration Platform for HCQ/CQ Pooled Analyses
Background: Results from observational studies and randomized clinical trials (RCTs) have led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective for COVID-19 prevention or treatment. Pooling individual participant data, including unanalyzed data from trials terminated early, enables more detailed investigation of the efficacy and safety of HCQ/CQ among subgroups of hospitalized patients. Methods: We searched ClinicalTrials.gov in May and June 2020 for US-based RCTs evaluating HCQ/CQ in hospitalized COVID-19 patients in which the outcomes defined in this study were recorded or could be extrapolated. The primary outcome was a 7-point ordinal scale measured between day 28 and 35 post enrollment; comparisons used proportional odds ratios. Harmonized de-identified data were collected via a common template spreadsheet sent to each principal investigator. The data were analyzed by fitting a prespecified Bayesian ordinal regression model and standardizing the resulting predictions. Results: Eight of 19 trials met eligibility criteria and agreed to participate. Patient-level data were available from 770 participants (412 HCQ/CQ vs 358 control). Baseline characteristics were similar between groups. We did not find evidence of a difference in COVID-19 ordinal scores between days 28 and 35 post-enrollment in the pooled patient population (odds ratio, 0.97; 95% credible interval, 0.76–1.24; higher favors HCQ/CQ), and found no convincing evidence of meaningful treatment effect heterogeneity among prespecified subgroups. Adverse event and serious adverse event rates were numerically higher with HCQ/CQ vs control (0.39 vs 0.29 and 0.13 vs 0.09 per patient, respectively). Conclusions: The findings of this individual participant data meta-analysis reinforce those of individual RCTs that HCQ/CQ is not efficacious for treatment of COVID-19 in hospitalized patients.

9 June 2023 in Medicine
Verified
Journal Article
Open access
OAon behalf of the Pandemic Response COVID-19 Research Collaboration Platform for ACEi/ARB Pooled Analyses
on behalf of the Pandemic Response COVID-19 Research Collaboration Platform for ACEi/ARB Pooled Analyses
LSLeon Di Stefano
Leon Di Stefano
MRMalathi Ram
Malathi Ram
DSDaniel O. Scharfstein
Daniel O. Scharfstein
TLTianjing Li
Tianjing Li
DFDaniel A. Freilich
Daniel A. Freilich
Background: Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs) have been hypothesized to benefit patients with COVID-19 via the inhibition of viral entry and other mechanisms. We conducted an individual participant data (IPD) meta-analysis assessing the effect of starting the ARB losartan in recently hospitalized COVID-19 patients. Methods: We searched ClinicalTrials.gov in January 2021 for U.S./Canada-based trials where an angiotensin-converting enzyme inhibitors/ARB was a treatment arm, targeted outcomes could be extrapolated, and data sharing was allowed. Our primary outcome was a 7-point COVID-19 ordinal score measured 13 to 16 days post-enrollment. We analyzed data by fitting multilevel Bayesian ordinal regression models and standardizing the resulting predictions. Results: 325 participants (156 losartan vs 169 control) from 4 studies contributed IPD. Three were randomized trials; one used non-randomized concurrent and historical controls. Baseline covariates were reasonably balanced for the randomized trials. All studies evaluated losartan. We found equivocal evidence of a difference in ordinal scores 13-16 days post-enrollment (model-standardized odds ratio [OR] 1.10, 95% credible interval [CrI] 0.76–1.71; adjusted OR 1.15, 95% CrI 0.15–3.59) and no compelling evidence of treatment effect heterogeneity among prespecified subgroups. Losartan had worse effects for those taking corticosteroids at baseline after adjusting for covariates (ratio of adjusted ORs 0.29, 95% CrI 0.08–0.99). Hypotension serious adverse event rates were numerically higher with losartan. Conclusions: In this IPD meta-analysis of hospitalized COVID-19 patients, we found no convincing evidence for the benefit of losartan versus control treatment, but a higher rate of hypotension adverse events with losartan.

24 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
Delphine MerinoDelphine Merino
Delphine Merino
TWT. S. Weber
T. S. Weber
ASA. Serrano
A. Serrano
FVF. Vaillant
F. Vaillant
KLK. Liu
K. Liu
SNS. H. Naik
S. H. Naik
The original version of this Article contained an error in Fig. 4. In the left histogram of the right panel of Fig. 4d, several data points were inadvertently deleted from the histogram during the production process. This error has been corrected in both the PDF and HTML versions of the Article. The original, incorrect version of Fig. 4 is presented in the accompanying Publisher Correction.